Related Experiment Video
Updated: Jun 13, 2026
09:16
Array Comparative Genomic Hybridization (Array CGH) for Detection of Genomic Copy Number Variants
Published on: February 21, 2015
Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic
Maija Wolf1, Miikka Korja, Ritva Karhu
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. maija.wolf@helsinki.fi
BMC Cancer
|May 7, 2010
Summary
A new framework integrating DNA, RNA, and tissue data identified a 12q24.31 gain as a prognostic biomarker for neuroblastoma. The gene DIABLO within this region is a potential therapeutic target for neuroblastoma progression.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Neuroblastoma research has identified oncogenes but few prognostic markers.
- Existing methods require novel frameworks for identifying new therapeutic targets and biomarkers.
Purpose of the Study:
- To develop and apply an integrated framework using DNA, RNA, and tissue data.
- To identify novel prognostic biomarkers and therapeutic targets for neuroblastoma.
Main Methods:
- Integrated array comparative genomic hybridization (aCGH) with gene expression profiling.
- Utilized FISH analysis on neuroblastoma tissue microarrays.
- Performed in silico data mining on public gene expression datasets.
Main Results:
- Identified copy number alterations and associated transcriptional changes in neuroblastoma.
- Discovered a low-level gain at 12q24.31 in 42% of neuroblastomas, correlating with intermediate prognosis.
- Found elevated expression of DIABLO within the 12q24.31 amplicon, suggesting a role in neuroblastoma progression.
Conclusions:
- The integrated framework successfully identified novel targets and biomarkers for neuroblastoma.
- A 12q24.31 gain is a potential new biomarker for neuroblastoma progression.
- DIABLO is a potential therapeutic target for neuroblastoma, requiring further investigation.
